TY - JOUR
T1 - Analysis of Prognostic Factors in Pancreatic Metastases
T2 - A Multicenter Retrospective Analysis
AU - Ito, Takashi
AU - Takada, Ryoji
AU - Omoto, Shunsuke
AU - Tsuda, Motoyuki
AU - Masuda, Daisuke
AU - Kato, Hironari
AU - Matsumoto, Toshihiko
AU - Moriyama, Ichiro
AU - Okabe, Yoshinobu
AU - Shiomi, Hideyuki
AU - Ishida, Etsuji
AU - Hatamaru, Keiichi
AU - Hashimoto, Shinichi
AU - Tanaka, Kiyohito
AU - Kawamoto, Hirofumi
AU - Yanagisawa, Akio
AU - Katayama, Toshiro
AU - Yazumi, Shujiro
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Pancreatic metastases (PMs) account for 1% to 2% of pancreatic tumors, and their prognostic significance is poorly defined. We evaluated the incidence and clinical characteristics of primary tumors and defined prognostic factors. Methods This retrospective study of 39 Japanese tertiary referral hospitals (January 2005 to August 2015) analyzed patient and tumor characteristics and survival time. Kaplan-Meier analysis and Cox proportional hazards models were applied to evaluate overall survival and prognostic factors, respectively. Results We enrolled 159 patients with a pathologic diagnosis of PM. The most common primary tumor was renal cell carcinoma (38.4%), followed by lung cancer (24.5%), colorectal cancer (11.3%), and sarcoma (6.3%). Eight patients were lost during follow-up, and 151 patients were included for statistical analysis. Median overall survival was 43.0 months, and the 5-year survival rate was 42.6%. Multivariate analysis identified 3 independent prognostic factors: extrapancreatic metastasis (hazard ratio, 2.13; 95% confidence interval, 1.11-4.07; P = 0.02), tumor-related symptoms at diagnosis (hazard ratio, 5.39; 95% confidence interval, 2.92-9.91; P < 0.001), and pathologic diagnosis of primary tumors (P < 0.001). Conclusions Treatment strategies and prognoses for PMs completely differ according to the primary tumor type. A definitive pathologic diagnosis of PMs is essential for selecting the appropriate treatment.
AB - Pancreatic metastases (PMs) account for 1% to 2% of pancreatic tumors, and their prognostic significance is poorly defined. We evaluated the incidence and clinical characteristics of primary tumors and defined prognostic factors. Methods This retrospective study of 39 Japanese tertiary referral hospitals (January 2005 to August 2015) analyzed patient and tumor characteristics and survival time. Kaplan-Meier analysis and Cox proportional hazards models were applied to evaluate overall survival and prognostic factors, respectively. Results We enrolled 159 patients with a pathologic diagnosis of PM. The most common primary tumor was renal cell carcinoma (38.4%), followed by lung cancer (24.5%), colorectal cancer (11.3%), and sarcoma (6.3%). Eight patients were lost during follow-up, and 151 patients were included for statistical analysis. Median overall survival was 43.0 months, and the 5-year survival rate was 42.6%. Multivariate analysis identified 3 independent prognostic factors: extrapancreatic metastasis (hazard ratio, 2.13; 95% confidence interval, 1.11-4.07; P = 0.02), tumor-related symptoms at diagnosis (hazard ratio, 5.39; 95% confidence interval, 2.92-9.91; P < 0.001), and pathologic diagnosis of primary tumors (P < 0.001). Conclusions Treatment strategies and prognoses for PMs completely differ according to the primary tumor type. A definitive pathologic diagnosis of PMs is essential for selecting the appropriate treatment.
KW - multicenter retrospective analysis
KW - pancreatic metastasis
KW - prognostic factors
UR - http://www.scopus.com/inward/record.url?scp=85051941994&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051941994&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000001132
DO - 10.1097/MPA.0000000000001132
M3 - Article
C2 - 30048381
AN - SCOPUS:85051941994
VL - 47
SP - 1033
EP - 1039
JO - Pancreas
JF - Pancreas
SN - 0885-3177
IS - 8
ER -